BR112017005554A2 - métodos para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e usos de pelo menos um biomarcador e de pelo menos um agente de ligação - Google Patents

métodos para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e usos de pelo menos um biomarcador e de pelo menos um agente de ligação

Info

Publication number
BR112017005554A2
BR112017005554A2 BR112017005554A BR112017005554A BR112017005554A2 BR 112017005554 A2 BR112017005554 A2 BR 112017005554A2 BR 112017005554 A BR112017005554 A BR 112017005554A BR 112017005554 A BR112017005554 A BR 112017005554A BR 112017005554 A2 BR112017005554 A2 BR 112017005554A2
Authority
BR
Brazil
Prior art keywords
heart failure
subject
chronic heart
predicting
risk
Prior art date
Application number
BR112017005554A
Other languages
English (en)
Inventor
Zaugg Christian
Block Dirk
Kaiser Edelgard
Karl Johann
Latini Roberto
Masson Serge
DIETERLE Thomas
Wienhues-Thelen Ursula-Henrike
ROLNY Vinzent
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54476920&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017005554(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017005554A2 publication Critical patent/BR112017005554A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a presente invenção refere-se a um método para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e/ou de hospitalização devido à insuficiência cardíaca crônica e/ou morte. o método é baseado na determinação de pelo menos um biomarcador selecionado a partir do grupo que consiste em um peptídeo tipo bnp, igfbp7 (proteína 7 de ligação a igf), uma troponina cardíaca, st2 solúvel (sst2), fgf-23 (fator de crescimento de fibroblastos 23) e fator de diferenciação de crescimento 15 (gdf-15), em uma amostra de um sujeito. o método pode ainda englobar a avaliação da presença ou ausência de (i) encurtamento fracional da parede média anormal ou (ii) hipertrofia ventricular esquerda. ainda contemplados pela presente invenção são os dispositivos adaptados para realizar a presente invenção.
BR112017005554A 2014-10-29 2015-10-28 métodos para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e usos de pelo menos um biomarcador e de pelo menos um agente de ligação BR112017005554A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14190836 2014-10-29
EP14192653 2014-11-11
PCT/EP2015/075012 WO2016066698A1 (en) 2014-10-29 2015-10-28 Biomarkers for risk prediction of mortality

Publications (1)

Publication Number Publication Date
BR112017005554A2 true BR112017005554A2 (pt) 2018-01-23

Family

ID=54476920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005554A BR112017005554A2 (pt) 2014-10-29 2015-10-28 métodos para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e usos de pelo menos um biomarcador e de pelo menos um agente de ligação

Country Status (8)

Country Link
US (2) US10557858B2 (pt)
EP (3) EP4300104A2 (pt)
JP (2) JP6803833B2 (pt)
KR (1) KR102064045B1 (pt)
CN (2) CN107110871B (pt)
BR (1) BR112017005554A2 (pt)
ES (1) ES2708325T5 (pt)
WO (1) WO2016066698A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
KR102368403B1 (ko) * 2017-12-13 2022-02-25 에프. 호프만-라 로슈 아게 뇌졸중의 예측을 위한 순환하는 안지오포이에틴-2(Ang-2)와 인슐린-유사 성장 인자-결합 단백질 7(IGFBP7)
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
KR102257830B1 (ko) * 2018-12-18 2021-05-28 연세대학교 산학협력단 사망 위험도의 예측 방법 및 이를 이용한 디바이스
KR102168304B1 (ko) * 2019-08-07 2020-10-21 한림대학교 산학협력단 인공호흡 삽관 환자의 nox4 농도 측정으로 탈관 예후 또는 28일 사망률을 예측하는 방법
JP2023526858A (ja) * 2020-05-19 2023-06-23 ファルコン バイオサイエンス エルエルシー 灌流低下を特徴とする状態の検出および治療
US20210375455A1 (en) * 2020-05-27 2021-12-02 MediSync, Inc. Artificial intelligence systems that incorporate expert knowledge related to heart failure
KR102484681B1 (ko) * 2022-05-11 2023-01-06 주식회사 이지스헬스케어 임상 의사 결정의 방법 및 시스템

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
AU5067100A (en) 1999-05-17 2000-12-05 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7998683B2 (en) 2006-04-24 2011-08-16 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
WO2008089994A1 (en) * 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
WO2008107201A1 (en) 2007-03-08 2008-09-12 Roche Diagnostics Gmbh Use of slim-1 in the assessment of heart failure
WO2009040133A1 (en) * 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
CA2710035C (en) * 2007-12-21 2018-01-16 Mcmaster University Method for assessing risk of heart failure
WO2009100907A1 (en) * 2008-02-14 2009-08-20 Dianeering Diagnostics Engineering And Research Gmbh Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers
JP5524182B2 (ja) 2008-04-30 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｓｆｒｐ−３の使用
US20090326053A1 (en) * 2008-05-30 2009-12-31 Trustees Of Boston University Diagnostic uses of follistatin-like 1
WO2009150253A1 (en) * 2008-06-13 2009-12-17 F. Hoffmann La-Roche Ag Assessment of complications of patients with type 1 diabetes
CN102187228A (zh) 2008-10-17 2011-09-14 霍夫曼-拉罗奇有限公司 双糖链蛋白聚糖在心力衰竭评估中的用途
JP2012524282A (ja) 2009-04-27 2012-10-11 エフ．ホフマン−ラ ロシュ アーゲー 心不全のマーカーとしてのエンドスタチンの使用
EP2529235B1 (en) 2010-01-29 2019-03-06 Metanomics GmbH Means and methods for diagnosing heart failure in a subject
CA2807213C (en) * 2010-08-26 2022-06-28 F. Hoffman-La Roche Ag Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
US20130338027A1 (en) 2012-06-15 2013-12-19 Nuclea Biotechnologies, Inc. Predictive Markers For Cancer and Metabolic Syndrome
JP6247302B2 (ja) * 2012-09-12 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 異常な短縮率（ｆｒａｃｔｉｏｎａｌｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
ES2939018T3 (es) * 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica

Also Published As

Publication number Publication date
KR102064045B1 (ko) 2020-01-08
EP3213085B2 (en) 2022-09-28
CN107110871A (zh) 2017-08-29
JP2017536537A (ja) 2017-12-07
US20170227552A1 (en) 2017-08-10
US10557858B2 (en) 2020-02-11
EP3521829A2 (en) 2019-08-07
ES2708325T5 (es) 2023-02-17
EP4300104A2 (en) 2024-01-03
JP7114677B2 (ja) 2022-08-08
EP3213085B1 (en) 2018-12-12
US20200371114A1 (en) 2020-11-26
EP3521829A3 (en) 2019-09-18
WO2016066698A1 (en) 2016-05-06
CN110514846A (zh) 2019-11-29
ES2708325T3 (es) 2019-04-09
EP3213085A1 (en) 2017-09-06
JP6803833B2 (ja) 2020-12-23
CN107110871B (zh) 2019-09-27
JP2021043218A (ja) 2021-03-18
KR20170063880A (ko) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112017005554A2 (pt) métodos para predizer o risco de um sujeito progredir rapidamente para insuficiência cardíaca crônica e usos de pelo menos um biomarcador e de pelo menos um agente de ligação
BR112016022620A2 (pt) cdna que codifica um polipeptídeo de fusão, vetor, célula procariotica ou eucariotica, sequência polinucleotídica, polipeptídeo de fusão, anticorpo ou fragmento de ligação, par de primers, sonda oligonucleotídica, oligonucleotídeo, sirna dirigido a um rna mensageiro, inibidor da atividade quinase fgfr, método de terapia e método para identificar um composto
BR112017005730A2 (pt) predição de evento de risco cardiovascular e usos da mesma
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
WO2014193999A3 (en) Biomarker methods and compositions
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112016009099A2 (pt) Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
BR112014021897A2 (pt) nova fusão fgfr3
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
WO2015014794A8 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
EP3399315A3 (en) Biomarkers in the selection of therapy of heart failure
MX2017005021A (es) Biomarcadores y metodos de prediccion.
BR112018067990A2 (pt) cromogranina a como um marcador para câncer de bexiga
BR112017003608A2 (pt) ?método para a análise comparativa do nível de expressão de mirna(s) alvo(s), dispositivo de análise da expressão de mirna, programa(s) para uma análise comparativa do(s) nível(eis) de expressão de mirna(s), meio de gravação legível por computador e chip para análise da expressão de mirna?
BR112021019032A2 (pt) Vetores de fator h e usos dos mesmos
BR112018009245A2 (pt) drimenol sintases iii
BR112017006569A2 (pt) composição, método para produzir uma composição, método para detectar anticorpos, uso de uma composição e kit de reagentes para a detecção de anticorpos
BR112018071395A2 (pt) métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso
BR112018009879A2 (pt) biomarcador da doença renal policística e seus usos
Widén et al. Assessment of multifactorial coronary artery disease by utilizing genomic data
ES2571302A1 (es) Procedimiento para la valoración secuencial por western-blot en una misma muestra de la proteína NCAM y de su cola de ácido polisiálico (PSA)
BR112021021626A2 (pt) Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica
Sun et al. The expression of THBS2 and its correlation with prognosis in gastric cancer
Guo et al. Prognostic study in ST-elevated myocardial infarction patients with or without left ventricular aneurysms
Abdelmonem et al. BRAIN NATRIURETIC PEPTIDE AS A PREDICTOR OF ADVERSE CARDIAC EVENTS AFTER SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH ACUTE CORONARY SYNDROME

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time